

Elafibranor for previously treated primary biliary cholangitis

Information for the public

Published: 14 November 2024

www.nice.org.uk

Elafibranor (Iqirvo) is available on the NHS. It is a possible treatment for primary biliary cholangitis in adults, when used:

- with ursodeoxycholic acid (UDCA), if the condition has not responded well enough to UDCA, or
- alone, if UDCA cannot be tolerated.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on primary biliary cholangitis](#) may be a good place to find out more.

These organisations can give you advice and support:

- [PBC Foundation](#), 0131 556 6811
- [British Liver Trust](#), 0800 652 7330
- [Liver4Life](#), 0800 074 3494

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6605-9